Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinicTimothy A. Chan, Solange Peters|Annals of Oncology|2018Cited by 2.9k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung CancerSolange Peters, Tony Mok, D. Ross Camidge et al.|New England Journal of Medicine|2017Cited by 2.4k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upDavid Planchard, Solange Peters, Sanjay Popat et al.|Annals of Oncology|2018Cited by 2.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyNicole M. Kuderer, Kerry L. Reynolds, Aakash Desai et al.|The Lancet|2020Cited by 1.8k
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upLizza Hendriks, Martin Reck, Keith M. Kerr et al.|Annals of Oncology|2023Cited by 782